报告要点 [Table_Summary] 公司发布 2025 年半年报，2025H1 实现营收 8.59 亿元，同比增长 42.43%；归母净利润 3.92 亿元，同比增长 26.65%。单二季度，公司实现营收 4.92 亿元，同比增长 30.44%；归母净利 润 2.24 亿元，同比增长 7.4%。 分析师及联系人 [Table_Author] 丨证券研究报告丨 公司研究丨点评报告丨锦波生物（832982.BJ） [Table_Title] 锦波生物 2025 年中报点评：收入韧性凸显，凝 胶贡献第二增长曲线 SAC：S0490514080004 SAC：S0490520080019 SFC：BUV258 李锦 罗祎 曾维朵 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 锦波生物（832982.BJ） cjzqdt11111 [Table_Title 锦波生物 2025 2] 年中报点评：收入韧性凸显，凝 胶贡献第二增长曲线 [Table_Summary2] 事件描述 公司发布 2025 年半年报，2025H1 实现营收 8.59 亿元，同比增长 42.43 ...

Group 1 - The financing balance of the Beijing Stock Exchange (BSE) reached a new high of 7.364 billion yuan as of September 4, 2025, indicating strong market resilience and investor confidence [1][9][22] - The financing balance of the BSE has shown a consistent upward trend, with significant increases observed during three market rallies in November 2023, September 2024, and February 2025 [1][11][14] - The proportion of financing balance to market capitalization for the BSE is 1.17%, significantly lower than that of the Sci-Tech Innovation Board (2.90%) and the Growth Enterprise Market (3.49%), suggesting potential for future growth in financing [1][14][15] Group 2 - The BSE's average daily trading volume reached 35.971 billion yuan, a 7.82% increase from the previous week, reflecting improved liquidity in the market [2][26][28] - The BSE 50 Index closed at 1,618.18 points with a TTM PE ratio of 79.12, indicating a solid valuation level [2][27][29] - The top three companies by financing balance on the BSE are Jinbo Biological, Better Ray, and Shuguang Digital, with financing balances of 327 million yuan, 270 million yuan, and 230 million yuan respectively [18][22][23] Group 3 - The report highlights the performance of various sectors, with the TTM PE ratios for high-end equipment, information technology, new chemical materials, consumer services, and pharmaceutical biology being 46.83, 110.99, 51.38, 63.12, and 48.25 respectively [2][37][39] - The report suggests focusing on technology growth, self-sufficiency, anti-involution, and energy storage sectors following the release of semi-annual reports [2][41][42] - The report indicates that the number of companies with a TTM PE ratio exceeding 45 has increased, with 158 companies now in this category, reflecting a shift in valuation structure [2][31][35]

Group 1 - The medical beauty sector experienced a rise of 3.39% on September 5, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] - Major stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 190.83, up 3.67%, and Huaxi Biological closing at 57.14, up 3.23% [1] Group 2 - The medical beauty sector saw a net inflow of 36.38 million yuan from institutional investors, while retail investors experienced a net outflow of 44.71 million yuan [1] - The trading volume for Ai Meike was 45,900 hands, with a transaction amount of 858 million yuan [1] - The stock performance of other companies in the sector included *ST Meigu, which closed at 3.17, up 0.63%, and Jinbo Biological, which closed at 302.39, down 0.86% [1]

Market Overview - The medical beauty sector experienced a decline of 1.3% on September 4, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Individual Stock Performance - ST Meigu closed at 3.15, with a slight increase of 0.32% and a trading volume of 95,700 shares, amounting to a transaction value of 30.34 million yuan [1] - Huaxi Biological closed at 55.35, down 0.66%, with a trading volume of 46,700 shares and a transaction value of 25.9 million yuan [1] - Aimeike closed at 184.07, down 1.83%, with a trading volume of 41,200 shares and a transaction value of 763 million yuan [1] - Jinbo Biological closed at 305.00, down 3.81%, with a trading volume of 9,732.97 shares and a transaction value of 301 million yuan [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 58.64 million yuan from institutional investors, while retail investors had a net inflow of 24.48 million yuan [1] - The overall capital flow indicates a mixed sentiment, with retail investors showing some interest despite the institutional outflow [1]

Group 1 - The core viewpoint of the articles highlights the positive performance of companies listed on the Beijing Stock Exchange (北交所), with 274 companies reporting over 6% year-on-year revenue growth in the first half of the year, outperforming the overall A-share market [1] - In the second quarter, Beijing Stock Exchange companies achieved a total revenue of 50.547 billion yuan, representing a quarter-on-quarter growth of 21.75%, and a net profit of 3.133 billion yuan, with a quarter-on-quarter increase of 12.88% [1] - The top 50 companies by market capitalization on the Beijing Stock Exchange generated a total revenue of 37.474 billion yuan in the first half, with a year-on-year growth of 6.97%, and a net profit of 3.214 billion yuan, reflecting a year-on-year increase of 2.66% [1] Group 2 - Over 20 companies on the Beijing Stock Exchange plan to distribute mid-term dividends, with Jinbo Biological (锦波生物) proposing a cash dividend of 10 yuan per 10 shares, amounting to a total dividend of 115 million yuan [2] - The outlook for the Beijing Stock Exchange suggests a focus on technology growth, self-sufficiency, and sectors such as military and specialized small giant companies, which represent new productive forces [2] - Investment strategies for the second half of the year recommend focusing on new productive sectors like artificial intelligence and new consumption, as well as selecting companies based on financial metrics that show high growth potential and strong R&D investment [2]

Core Viewpoint - The A-share market shows a mixed performance with the Shanghai Composite Index closing above the six-month moving average, indicating potential bullish sentiment among investors [1] Group 1: Market Overview - As of 13:59 today, the Shanghai Composite Index stands at 3814.20 points, with a decline of 1.14% [1] - The total trading volume in the A-share market reached 1,878.28 billion yuan [1] Group 2: Stocks Breaking the Six-Month Moving Average - Thirteen A-shares have surpassed the six-month moving average today, with notable stocks including Renfu Pharmaceutical, Guofeng New Materials, and Zhizheng Co., which have deviation rates of 8.65%, 4.92%, and 4.08% respectively [1] - Stocks with smaller deviation rates that have just crossed the six-month moving average include Jinbo Biological, ST Huawen, and *ST Zhongzhuang [1] Group 3: Individual Stock Performance - Renfu Pharmaceutical (600079) experienced a price increase of 9.99% with a turnover rate of 8.87%, closing at 22.57 yuan, showing a deviation rate of 8.65% from the six-month moving average [1] - Guofeng New Materials (000859) rose by 6.13% with a turnover rate of 9.75%, closing at 7.10 yuan, reflecting a deviation rate of 4.92% [1] - Zhizheng Co. (603991) saw a 4.74% increase with a turnover rate of 4.15%, closing at 63.48 yuan, with a deviation rate of 4.08% [1]

Core Viewpoint - The performance of listed medical beauty companies in China shows significant divergence in the first half of 2025, with major players in the hyaluronic acid market facing growth bottlenecks, while companies in the recombinant collagen segment are experiencing substantial growth [1][2][7]. Group 1: Performance of Major Companies - Huaxi Biological reported revenue of 2.261 billion yuan, a year-on-year decline of 19.57%, and a net profit of 221 million yuan, down 35.38% [1][2]. - Haohai Biological achieved revenue of 1.304 billion yuan, a decrease of 7.12%, with a net profit of 211 million yuan, down 10.29% [1][2]. - Aimeike's revenue was 1.299 billion yuan, down 21.59%, with a net profit of 789 million yuan, a decline of 29.57% [1][2]. - In contrast, Jinbo Biological, the first stock of recombinant collagen on the Beijing Stock Exchange, reported revenue of 859 million yuan, an increase of 42.43%, and a net profit of 392 million yuan, up 26.65% [1][2]. - Giant Biological's revenue reached 3.113 billion yuan, a year-on-year increase of 21.66%, with a net profit of 1.182 billion yuan, up 20.23% [1][2]. Group 2: Market Trends and Competition - The medical beauty market in China has seen rapid growth, with the market size increasing from 99.3 billion yuan in 2017 to 189.2 billion yuan in 2021, reflecting a compound annual growth rate of 17.5% [4]. - The competition in the hyaluronic acid sector has intensified, leading to price reductions and impacting the performance of leading companies [4][6]. - The demand for aesthetic products is evolving, with a shift towards user-oriented solutions and a growing emphasis on product innovation and technology [3][7]. Group 3: Strategic Adjustments and Innovations - Huaxi Biological is shifting its marketing strategy to focus on brand building and consumer engagement through platforms like Xiaohongshu and WeChat, moving away from price-driven promotions [5]. - Haohai Biological is also adapting its product offerings, with new high-end hyaluronic acid products showing promising market performance [6]. - The recombinant collagen market is projected to grow significantly, with estimates suggesting it will reach 585.7 billion yuan by 2025, driven by new product launches and market expansion [8][9]. Group 4: Regulatory and International Expansion - The medical beauty industry is witnessing an increase in compliant products, with several companies obtaining third-class medical device registration certificates, enhancing market offerings [10][11]. - Companies like Huaxi Biological and Haohai Biological are actively pursuing international markets, with Huaxi reporting significant revenue from overseas operations [11][12]. - Aimeike's acquisition of a majority stake in a South Korean company highlights the trend of domestic firms expanding their global footprint [12].

Core Viewpoint - The performance of listed medical beauty companies in China shows significant divergence in the first half of 2025, with major players in the hyaluronic acid market facing growth bottlenecks while companies in the collagen reconstruction sector are experiencing substantial growth [1][2]. Group 1: Performance of Major Companies - Huaxi Biological reported revenue of 2.261 billion yuan, a year-on-year decline of 19.57%, and a net profit of 221 million yuan, down 35.38% [2]. - Haohai Biological achieved revenue of 1.304 billion yuan, a decrease of 7.12%, with a net profit of 211 million yuan, down 10.29% [2]. - Aimeike's revenue was 1.299 billion yuan, down 21.59%, with a net profit of 789 million yuan, a decline of 29.57% [2]. - In contrast, Jinbo Biological, the first stock of collagen reconstruction on the Beijing Stock Exchange, reported revenue of 859 million yuan, an increase of 42.43%, and a net profit of 392 million yuan, up 26.65% [1][2]. Group 2: Market Dynamics - The medical beauty industry is undergoing a transformation driven by increasing aesthetic demands and technological upgrades, necessitating higher core technology and product innovation capabilities from companies [3]. - The competition in the hyaluronic acid sector has intensified, with a significant increase in supply and aggressive pricing strategies from downstream medical beauty institutions [4]. - The market for collagen reconstruction products is rapidly growing, with projections indicating a compound annual growth rate of 44.93%, reaching 585.7 billion yuan by 2025 [9][10]. Group 3: Strategic Adjustments - Companies like Huaxi Biological are shifting from a traffic-driven sales model to a brand communication strategy based on scientific validation, aiming to enhance brand efficacy and customer acquisition [5][6]. - Haohai Biological is focusing on high-end hyaluronic acid products, with the "Haimeiyuebai" product showing promising market performance despite overall revenue declines in its hyaluronic acid segment [7]. - Aimeike acknowledges the shift towards a user-oriented market, emphasizing the importance of product innovation and systematized competition [8]. Group 4: Regulatory and International Expansion - The medical beauty industry is witnessing an increase in compliant products, with several companies obtaining third-class medical device registration certificates, enhancing market options [11][12]. - Companies are actively pursuing international markets, with Huaxi Biological reporting 331 million yuan in international raw material business revenue, accounting for 52.93% of its raw material income [12][13]. - Aimeike's acquisition of a majority stake in a South Korean company marks its strategic entry into the global regenerative injection market [13].

Group 1: Core Insights - In the first half of 2025, 47% of companies in the North Exchange's consumer services sector reported positive year-on-year growth in net profit attributable to shareholders [2][8] - The median revenue for these companies in H1 2025 was 236 million yuan, showing a slight decline of 0.36% year-on-year, while the median net profit attributable to shareholders was 15.23 million yuan, down 7.59% year-on-year [17][19] - In Q2 2025, the median revenue increased to 126 million yuan, reflecting a year-on-year growth of 1.88%, and the median net profit rose to 7.92 million yuan, marking a year-on-year increase of 4.5% [17][19] Group 2: Company Performance - Among the 38 companies, 14 reported both revenue and net profit growth in H1 2025, while 15 companies achieved sequential growth in both metrics in Q2 2025 [20][22] - Notable performers included Jinbo Biological, which achieved a revenue of 859 million yuan in H1 2025, a 42% increase year-on-year, and a net profit of 392 million yuan, up 26.65% [30] - Kangnong Seed Industry reported a significant increase in contract liabilities, up 410% year-on-year, indicating strong market acceptance of its products [26] Group 3: Market Trends - The median price-to-earnings (P/E) ratio for the consumer services sector increased from 51.7X to 51.8X, while the total market capitalization decreased from 126.47 billion yuan to 124.89 billion yuan [34][37] - The overall market performance for the consumer services sector showed a median decline of 1.99% in stock prices during the week of August 25 to August 29, 2025 [33][38] - The TTM median P/E ratio for the broader consumer sector rose by 8.98% to 72.3X, indicating a positive valuation trend [44][45] Group 4: Industry Insights - The TTM median P/E ratio for the food and beverage and agriculture sectors decreased from 47.9X to 45.8X, reflecting a shift in investor sentiment [46][47] - The professional technical services sector saw a decline in its TTM median P/E ratio from 32.2X to 31.2X, indicating potential challenges in valuation [50][51] - The consumer services sector's performance is influenced by various factors, including market competition and economic conditions, which are critical for future growth [2][8]

Core Viewpoint - The companies listed on the Beijing Stock Exchange (BSE) demonstrated strong resilience and vitality in their 2025 semi-annual reports, with a significant number achieving substantial revenue and profit growth despite a complex market environment [1][2]. Revenue Performance - A total of 208 companies reported revenues exceeding 100 million yuan, with 17 companies surpassing 1 billion yuan, marking them as the "revenue leaders" of the BSE [2]. - Among these, Better Ray (贝特瑞) led with a revenue of 7.838 billion yuan, a year-on-year increase of 11.36%, and a net profit of 479 million yuan [2]. - Other notable companies in terms of revenue include Yinuowei (一诺威) at 3.550 billion yuan, Tongli Co. (同力股份) at 3.169 billion yuan, and Ying Tai Bio (颖泰生物) at 2.966 billion yuan [2]. Profitability - Out of 223 companies, 82.29% reported positive net profits, indicating a robust profitability landscape [3]. - Seven companies achieved net profits exceeding 100 million yuan, with Better Ray again leading at approximately 479 million yuan, followed by Development Technology (开发科技) at 395 million yuan [3]. - Jinbo Bio (锦波生物) reported a revenue of 859 million yuan, a 42.43% increase year-on-year, and a net profit of 392 million yuan, reflecting a 26.65% growth [3]. Profit Growth - Approximately 50% of companies, or 136 in total, reported year-on-year growth in net profits, with 27 companies doubling their profits [4]. - Shibibai (拾比佰) turned a profit with a net profit of 29.226 million yuan, attributed to increased sales driven by government policies and improved internal management [4]. - Chuangyuan Xinke (创远信科) achieved a revenue of 111 million yuan, a growth of 18.44%, and a net profit of 6.3153 million yuan, marking a significant increase of 354.24% [4]. Dividend Distribution - Over 20 companies announced interim dividend plans, reflecting a commitment to returning value to investors [6]. - Jinbo Bio plans to distribute a cash dividend of 10 yuan per 10 shares, totaling approximately 115 million yuan [6]. - Guoxin Technology (广信科技) proposed its first dividend since listing, with a plan to distribute 6.56 yuan per 10 shares, amounting to around 60 million yuan [6].